-- Clover to leverage its established and growing commercial infrastructure to exclusively distribute Adimmune’s AdimFlu-S (QIS), the only imported quadrivalent influenza vaccine approved in mainland China ---- Partnership with Adimmune adds a second commercial-stage product to Clover’s respiratory virus vaccine portfolio, with influenza expected to be a growing and stable market in mainland China --

Read more:
Clover Enters into Exclusive Agreement to Commercialize Quadrivalent Seasonal Influenza Vaccine in Mainland China